NCT03097770View on ClinicalTrials.gov

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

May 10, 2019

Study Completion Date

January 31, 2020

Conditions
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaProlymphocytic LeukemiaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRefractory Chronic Lymphocytic LeukemiaStage III Adult Diffuse Large Cell LymphomaStage III Chronic Lymphocytic LeukemiaStage III Grade 1 Follicular LymphomaStage III Grade 2 Follicular LymphomaStage III Grade 3 Follicular LymphomaStage III Mantle Cell LymphomaStage IV Adult Diffuse Large Cell LymphomaStage IV Chronic Lymphocytic LeukemiaStage IV Grade 1 Follicular LymphomaStage IV Grade 2 Follicular LymphomaStage IV Grade 3 Follicular LymphomaStage IV Mantle Cell Lymphoma
Interventions
BIOLOGICAL

anti-CD19/20-CAR vector-transduced T cells

genetically engineered lymphocyte therapy

Trial Locations (1)

100853

Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER

NCT03097770 - Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | Biotech Hunter | Biotech Hunter